Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie Buys 5,000 Shares

Septerna, Inc. (NASDAQ:SEPN) CFO Gil M. Labrucherie purchased 5,000 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were acquired at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares of the company’s stock, valued at approximately $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Septerna Price Performance

Shares of Septerna stock opened at $5.80 on Friday. The company’s 50 day moving average price is $17.78. Septerna, Inc. has a 12 month low of $4.17 and a 12 month high of $28.99.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of SEPN. RA Capital Management L.P. bought a new stake in Septerna in the fourth quarter worth $160,205,000. TRV GP V LLC purchased a new position in shares of Septerna in the 4th quarter worth $142,337,000. TRV GP VI LLC bought a new stake in shares of Septerna in the 4th quarter worth about $72,191,000. Samsara BioCapital LLC purchased a new stake in shares of Septerna during the 4th quarter valued at about $63,399,000. Finally, Driehaus Capital Management LLC bought a new position in shares of Septerna in the 4th quarter valued at about $59,301,000.

Analyst Ratings Changes

Several analysts recently issued reports on SEPN shares. TD Cowen assumed coverage on Septerna in a research note on Tuesday, November 19th. They set a “buy” rating on the stock. Wells Fargo & Company cut shares of Septerna from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $43.00 to $14.00 in a research report on Tuesday, February 18th. JPMorgan Chase & Co. began coverage on shares of Septerna in a research report on Tuesday, November 19th. They set an “overweight” rating and a $38.00 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $50.00 target price on shares of Septerna in a research note on Tuesday, February 11th.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.